APA (7th ed.) Citation

WQ, C., JL, L., JK, T., TBU, L., GS, G., K, S., . . . BC, G. (2025). Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: A randomised, open-label, phase 2 trial. The Lancet. Oncology, 26(2), 175. https://doi.org/10.1016/S1470-2045(24)00677-6

Chicago Style (17th ed.) Citation

WQ, Chong, et al. "Pembrolizumab with or Without Bevacizumab in Platinum-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomised, Open-label, Phase 2 Trial." The Lancet. Oncology 26, no. 2 (2025): 175. https://doi.org/10.1016/S1470-2045(24)00677-6.

MLA (9th ed.) Citation

WQ, Chong, et al. "Pembrolizumab with or Without Bevacizumab in Platinum-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomised, Open-label, Phase 2 Trial." The Lancet. Oncology, vol. 26, no. 2, 2025, p. 175, https://doi.org/10.1016/S1470-2045(24)00677-6.